Dysregulation of mTOR activity through LKB1 inactivation

Chinese Journal of Cancer

Volumn 32, Issue 8, 2013, Pages 427-433

  Zhou, Wei ^a   Marcus, Adam I ^a   Vertino, Paula M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bi allelic inactivation; Energetic stress; Metabolism; Protein translation

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE LKB1; RAPAMYCIN; RAPAMYCIN DERIVATIVE;

ARTICLE; CELL ADHESION; CELL POLARITY; DRUG APPROVAL; ENZYME ACTIVATION; ENZYME DYSREGULATION; ENZYME MODIFICATION; FOOD AND DRUG ADMINISTRATION; GENE ACTIVATION; GENE INACTIVATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; NEOPLASM; NONHUMAN; SIGNAL TRANSDUCTION; STRESS;

ADENOCARCINOMA; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84881286031     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10086     Document Type: Article

References (67)

1. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet, 1998,18:38-43.
2. Collins SP, Reoma JL, Gamm DM, et al. LKB1, a novel serine/ threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem J2000,345 Pt 3:673-680.
3. Su JY, Rempel RE, Erikson E, et al. Cloning and characterization of the Xenopus cyclin-dependent kinase inhibitor p27XIC1. Proc Natl Acad Sci U S A, 1995,92:10187-10191.
4. Kemphues KJ, Priess JR, Morton DG, et al. Identification of genes required for cytoplasmic localization in early c. Elegans embryos. Cell, 1988,52:311-320.
5. Lizcano JM, Goransson O, Toth R, et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/ PAR-1. EMBO J, 2004,23:833-843.
6. Baas AF, Boudeau J, Sapkota GP, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J, 2003,22:3062-3072.
7. Boudeau J, Baas AF, Deak M, et al. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J, 2003,22:5102-5114.
8. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/ beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol, 2003,2:28.
9. Karuman P, Gozani O, Odze RD, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell, 2001,7:1307-1319.
10. Sapkota GP, Boudeau J, Deak M, et al. Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem J, 2002,362:481-490.
11. Sapkota GP, Kieloch A, Lizcano JM, et al. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/ STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth. J Biol Chem, 2001,276:19469-19482.
12. Esteve-Puig R, Canals F, Colome N, et al. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS ONE, 2009,4:e4771.
13. Zheng B, Jeong JH, Asara JM, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell, 2009,33:237-247.
14. Hawley SA, Davison M, Woods A, et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem, 1996,271:27879-27887.
15. Stein SC, Woods A, Jones NA, et al. The regulation of AMP-activated protein kinase by phosphorylation. Biochem J, 2000,345 Pt 3:437-443.
16. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol, 2003,13:2004-2008.
17. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem, 1998,67:821-855.
18. Mu J, Brozinick JT Jr, Valladares O, et al. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell, 2001,7:1085-1094.
19. Hong SP, Leiper FC, Woods A, et al. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci U S A, 2003,100:8839-8843.
20. Corradetti MN, Inoki K, Bardeesy N, et al. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev, 2004,18:1533-1538.
21. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 2004,6:91-99.
22. Brugarolas J, Kaelin WG Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell, 2004,6:7-10.
23. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A, 2004,101:3329-3335.
24. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature, 1998,391:184-187.
25. Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med, 1998,128:896-899.
26. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med, 1987,316:1511-1514.
27. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 2000,119:1447-1453.
28. Lim W, Hearle N, Shah B, et al. Further observations on LKB1/ STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer, 2003,89:308-313.
29. Shackelford DB, Vasquez DS, Corbeil J, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an Lkb1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A, 2009,106:11137-11142.
30. Katajisto P, Vaahtomeri K, Ekman N, et al. LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet, 2008,40:455-459.
31. Fu A, Ng AC, Depatie C, et al. Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab, 2009,10:285-295.
32. Granot Z, Swisa A, Magenheim J, et al. LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab, 2009,10:296-308.
33. Ikeda Y, Sato K, Pimentel DR, et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem, 2009,284:35839-35849.
34. Tanwar PS, Kaneko-Tarui T, Zhang L, et al. Altered LKB1/AMPK/ TSC1/TSC2/mTOR signaling causes disruption of sertoli cell polarity and spermatogenesis. Hum Mol Genet, 2012,21:4394- 4405.
35. Puffenberger EG, Strauss KA, Ramsey KE, et al. Polyhydramnios, megal encephal y and symptomati c epi l epsy caused by a homozygous 7-kilobase deletion in LYK5. Brain, 2007,130:1929-1941.
36. Orlova KA, Parker WE, Heuer GG, et al. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest, 2010,120:1591-1602.
37. Forgacs E, Biesterveld EJ, Sekido Y, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene, 1998,17:1557-1565.
38. Hosoya Y, Gemma A, Seike M, et al. Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer, 1999,25:87-93.
39. Massion PP, Taflan PM, Shyr Y, et al. Early involvement of the phosphatidy-linositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med, 2004,170:1088-1094.
40. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis, 2004.
41. Avizienyte E, Roth S, Loukola A, et al. Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res, 1998,58:2087-2090.
42. Bignell GR, Barfoot R, Seal S, et al. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res, 1998,58:1384-1386.
43. Wang ZJ, Churchman M, Campbell IG, et al. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer, 1999,80:70-72.
44. Sobot t ka SB, Haase M, Fitze G, et al. Frequent l oss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol, 2000,49:187-195.
45. Rowan A, Bataille V, MacKie R, et al. Somatic mutations in the Peutz-Jeghers (LKB1/STK11) gene in sporadic malignant melanomas. J Invest Dermatol, 1999,112:509-511.
46. Guldberg P, thor Straten P, Ahrenkiel V, et al. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene, 1999,18:1777-1780.
47. Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One, 2009,4:e5137.
48. McCabe MT, Powell DR, Zhou W, et al. Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. Cancer Genet Cytogenet, 2010,197:130-141.
49. Sahin F, Maitra A, Argani P, et al. Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol, 2003,16:686-691.
50. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol, 1999,154:1835-1840.
51. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res, 2002,62:3659-3662.
52. Carretero J, Medina PP, Pio R, et al. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene, 2004,23:4037-4040.
53. Zhong D, Guo L, de Aguirre I et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer, 2006,53:285-294.
54. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature, 2007,448:807-810.
55. Gill RK, Yang SH, Meerzaman D, et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene, 2011,30:3784-3791.
56. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell, 2012,150:1107-1120.
57. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell, 2012,150:1121-1134.
58. Hammerman PS, Hayes DN, Wilkerson MD, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature, 2012,489:519-525.
59. Carretero J, Medina PP, Blanco R, et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26:1616-1625.
60. Eggers CM, Kline ER, Zhong D, et al. STE20-related kinase adaptor protein alpha (STRADα) regulates cell polarity and invasion through PAK1 signaling in LKB1-null cells. J Biol Chem, 2012,287:18758-18768.
61. Zhong D, Liu X, Schafer-Hales K, et al. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther, 2008,7:809-817.
62. Wei C, Amos CI, Zhang N, et al. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res, 2008,14:1167-1171.
63. Wei C, Amos CI, Zhang N, et al. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. Cancer Lett, 2009,277:149-154.
64. Contreras CM, Akbay EA, Gallardo TD, et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech, 2010,3:181-193.
65. Shorning BY, Griffiths D, Clarke AR. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One, 2011,6:e16209.
66. Pearson HB, McCarthy A, Collins CM, et al. Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res, 2008,68:2223-2232.
67. Feng Y, Wang Y, Wang Z, et al. The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. Cancer Res, 2012,72:6502-6511.